RESUMEN
In an effort to identify CYP and hERG clean mPGES-1 inhibitors from the dihydrofuran-fused tricyclic benzo[d]imidazole series lead 7, an extensive structure-activity relationship (SAR) studies were performed. Optimization of A, D and E-rings in 7 afforded many potent compounds with human whole blood potency in the range of 160-950â¯nM. Selected inhibitors 21d, 21j, 21m, 21n, 21p and 22b provided selectivity against COX-enzymes and mPGES-1 isoforms (mPGES-2 and cPGES) along with sufficient selectivity against prostanoid synthases. Most of the tested analogs demonstrated required metabolic stability in liver microsomes, low hERG and CYP liability. Oral pharmacokinetics and bioavailability of lead compounds 21j, 21m and 21p are discussed in multiple species like rat, guinea pig, dog, and cynomolgus monkey. Besides, these compounds revealed low to moderate activity against human pregnane X receptor (hPXR). The selected lead 21j further demonstrated in vivo efficacy in acute hyperalgesia (ED50: 39.6â¯mg/kg) and MIA-induced osteoarthritic pain models (ED50: 106â¯mg/kg).
Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Inhibidores Enzimáticos/farmacología , Canales de Potasio Éter-A-Go-Go/metabolismo , Furanos/farmacología , Imidazoles/farmacología , Prostaglandina-E Sintasas/antagonistas & inhibidores , Administración Oral , Animales , Línea Celular Tumoral , Perros , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/química , Furanos/administración & dosificación , Furanos/química , Cobayas , Humanos , Hiperalgesia/tratamiento farmacológico , Imidazoles/administración & dosificación , Imidazoles/química , Macaca fascicularis , Estructura Molecular , Dolor/tratamiento farmacológico , Prostaglandina-E Sintasas/metabolismo , Ratas , Relación Estructura-ActividadRESUMEN
This letter describes the synthesis and biological evaluation of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as novel mPGES-1 inhibitors, capable of inhibiting an increased PGE2 production in the disease state. Structure-activity optimization afforded many potent mPGES-1 inhibitors having <50â¯nM potencies in the A549 cellular assay and adequate metabolic stability in liver microsomes. Lead compounds 8l and 8m demonstrated reasonable in vitro pharmacology and pharmacokinetic properties over other compounds. In particular, 8m revealed satisfactory oral pharmacokinetics and bioavailability in multiple species like rat, guinea pig, dog and cynomolgus monkey. In addition, the representative compound 8m showed in vivo efficacy by inhibiting LPS-induced thermal hyperalgesia with an ED50 of 14.3â¯mg/kg in guinea pig.
Asunto(s)
Inhibidores Enzimáticos/química , Furanos/química , Imidazoles/química , Prostaglandina-E Sintasas/antagonistas & inhibidores , Células A549 , Administración Oral , Animales , Perros , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/uso terapéutico , Cobayas , Semivida , Humanos , Hiperalgesia/tratamiento farmacológico , Imidazoles/farmacocinética , Imidazoles/uso terapéutico , Concentración 50 Inhibidora , Macaca fascicularis , Microsomas Hepáticos/metabolismo , Prostaglandina-E Sintasas/metabolismo , Ratas , Solubilidad , Relación Estructura-ActividadRESUMEN
A novel series of N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides was identified as transient receptor potential melastatin 8 (TRPM8) channel blockers through analogue-based rational design, synthesis and screening. Details of the synthesis, effect of aryl groups and their substituents on in-vitro potency were studied. The effects of selected functional groups on the 4-position of the chromene ring were also studied, which showed interesting results. The 4-hydroxy derivatives showed excellent potency and selectivity. Optical resolution and screening of alcohols revealed that (R)-(-)-isomers were in general more potent than the corresponding (S)-(+)-isomers. The isomer (R)-(-)-10e (IC50: 8.9nM) showed a good pharmacokinetic profile upon oral dosing at 10mg/kg in Sprague-Dawley (SD) rats. The compound (R)-(-)-10e also showed excellent efficacy in relevant rodent models of neuropathic pain.